TG Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Briumvi continues to gain market share in MS, surpassing $1 billion in sales and driving strong revenue growth. Key initiatives for 2026 include expanding the sales force, launching patient awareness campaigns, and advancing pivotal trials for new dosing and subcu formulations. Briumvi's pipeline and patent life support long-term growth.
Fiscal Year 2025
-
Delivered $616M global revenue in 2025, driven by 92% year-over-year BRIUMVI growth and strong Q4. Reaffirmed 2026 guidance of $825–$850M U.S. net revenue, with continued share gains, robust pipeline progress, and expanded commercial initiatives.
-
Briumvi is targeting $585 million in revenue this year, with significant growth expected next year. Market share gains are tied to increasing patient awareness, and targeted sales force expansion is underway. Sub-Q and CAR-T programs are progressing, with key data expected in 2024 and 2026.
-
Briumvi is gaining first-line IV status due to strong data, convenience, and robust patient support. SUB-Q formulation is expected to nearly double the addressable market, with pivotal trial data anticipated by late 2025 or early 2027. Q4 growth is expected to outpace Q3, and direct-to-consumer efforts will expand in 2026.
-
Q3 saw record BRIUMVI sales, 93% revenue growth year-over-year, and raised 2025 guidance to $585M. Profitability continued for a sixth quarter, with strong patient retention, expanding field force, and pipeline progress supporting long-term growth.
-
The company is expanding its market share in the IV MS therapy segment, with strong real-world efficacy and tolerability data. Key pipeline developments include a subcutaneous formulation and a new dosing regimen, with pivotal data expected in 2026–2028. Early-stage programs and ex-US partnerships are progressing, but US sales remain the primary revenue driver.
-
A new $100 million share buyback was announced, and BRIUMVI continues to outperform expectations, with a shift toward direct-to-patient marketing and strong market share growth. Subcutaneous BRIUMVI could nearly double the market opportunity, and business development remains a strategic focus.
-
Q2 2025 saw 91% year-over-year revenue growth, driven by BRIUMVI's expanding market share and strong patient persistence. Full-year revenue guidance was raised to $570–$575 million, with continued investment in SubQ and IV enhancements and a robust cash position of $279 million.
-
BRIUMVI continues to grow in market share and prescriber base, with steady revenue guidance and ongoing product enhancements such as a consolidated dose and subcutaneous formulation. Commercial and marketing efforts are expanding incrementally, while financial strategy focuses on reinvestment and pipeline development.
-
CD20 therapies are expanding in the MS market, with subQ options gaining share and IV remaining dominant. BRIUMVI aims for top market position through innovation, expanded marketing, and new dosing regimens, with pivotal trial data and potential label updates expected by 2027-2028.
-
Q1 2025 delivered strong BRIUMVI sales growth, with revenue up 137% year-over-year and guidance raised to $560 million for the full year. Market share gains, robust patient demand, and new product innovations support a positive outlook.
-
Briumvi continues to gain market share in the competitive MS space, driven by its efficacy, safety, and efficient commercial strategy. Plans include expanding into the subcutaneous market, launching pivotal trials, and targeting $540 million in 2025 global revenue.
Fiscal Year 2024
-
2024 saw record BRIUMVI sales, strong clinical data, and international expansion, with 2025 guidance raised to $525M in U.S. revenue. Key pipeline advances include subcutaneous and enhanced IV regimens, plus new autoimmune indications.
-
The company highlighted strong BRIUMVI performance, raising guidance and seeing continued growth in both breadth and depth of adoption. SubQ formulation progress and a new manufacturing plant were discussed, alongside a promising allogeneic CAR-T pipeline for autoimmune diseases.
-
Q3 Briumvi net sales reached $83.3M, up 15% sequentially and over 230% year-over-year, driving raised full-year guidance to $300–$305M. Hospital adoption and long-term efficacy data support continued growth, with strong cash reserves and ongoing investments in commercialization and R&D.
-
Q2 2024 saw Briumvi net sales of $72.6M, 350% higher year-over-year, with full-year guidance raised to $290–$300M. Operational profitability was achieved, a $250M credit facility was secured, and a $100M share repurchase program launched.
-
BRIUMVI is on track for $270M–$290M in 2024 revenue, with strong adoption in both community and hospital settings. The company is expanding its sales force, advancing SUB-Q and CAR T-cell programs, and targeting leadership in the IV CD20 market.
-
Briumvi continues strong growth in the MS market, with expanding market share and robust commercial execution. New patents extend exclusivity to 2042, supporting plans for additional indications and a subcutaneous version. A CD19 allogeneic CAR T program is also advancing.